Bovine Lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trials
- Authors: Manzoni, P; Stolfi, I; Messner, H; Cattani, S; La Forgia, N; Romeo, MG; Bollani, L; Rinaldi, M; Gallo, E; Quercia, M; Maule, M; Decembrino, L; Magaldi, R; Mosca, F; Vagnarelli, E; Memo, L; Betta, PM; Stronati, M; Farina, D; Borghesi, A; Tzialla, C; Agriesti, G; Arisio, R; Franco, C; Del Sordo, P; Guardione R; Boano, E; Catarinella, A; Romano, C; Rizzollo, S; Barberis, L; Monetti, C; Sala, U; Carbonara, C; Mastretta, E; Priolo, C; Galletto, P; Campagnoli, F; Vivalda, M; Cuozzo, M; Bonfante, G; Gomirato, G; Giovannozzi, C; Cipolla, D; Corsello, G; Natale, F; Corona, G; Tumminelli, F; Vetrano, G; Tridapalli, E; Faldella, G; Picone, SV; Paolillo, PM; Caliendo, E; Pugni, L; Gargano, G; Magnani, C; Renzullo, L; Bordignon, L; Saia, OS; Della Casa, E; Ferrari, F; Pedicino, R
- Publication year: 2012
- Type: Articolo in rivista (Articolo in rivista)
- OA Link: http://hdl.handle.net/10447/277195
Abstract
BACKGROUND: Lactoferrin is a mammalian milk glycoprotein involved in innate immunity. Recent data show that bovine lactoferrin (bLF) prevents late-onset sepsis in preterm very low birth weight (VLBW) neonates. METHODS: This is a secondary analysis of data from a multicenter randomized controlled trial where preterm VLBW neonates randomly received bLF (100 mg/day; group A1), bLF + Lactobacillus rhamnosus GG (106 colony-forming units per day; group A2), or placebo (group B) for 6 weeks. Here we analyze the incidence rates of fungal colonization, invasive fungal infection (IFI), and rate of progression from colonization to infection in all groups. RESULTS: This study included 472 neonates whose clinical, nutritional, and demographical characteristics were similar. Overall, the incidence of fungal colonization was comparable (17.6%, 16.6%, and 18.5% in A1, A2, and B, respectively; P = .89 [A1] and .77 [A2]). In contrast, IFIs were significantly decreased in A1 and A2 (0.7% and 2.0%, respectively) compared with B (7.7%; P = .002 [A1] and .02 [A2]), and this was significantly true both in <1000 g (0.9% [A1] and 5.6% [A2], vs 15.0%) and in 1001 to 1500 g infants (0% and 0% vs 3.7%). The progression rate colonization-infection was significantly lower in the bLF groups: 3.7% (A1) and 12% (A2), vs 41.9%; P < .001 (A1) and P = .02 (A2). No IFI-attributable deaths occurred in the treatment groups, versus 2 in placebo. No adverse effects or intolerances occurred. CONCLUSIONS: Prophylactic oral administration of bLF reduces the incidence of IFI in preterm VLBW neonates. No effect is seen on colonization. The protective effect on IFI is likely due to limitation of ability of fungal colonies to progress toward invasion and systemic disease in colonized infants